rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Braveheart Bio, Inc.

BRVE · Nasdaq

Health CareBiotechnology

We hold no 150-day reading for BRVE yet: it needs about 200 sessions of history. Biotechnology: 16% of its 561 stocks in an uptrend (−15 points in four weeks); Health Care: 26% (−10 points in four weeks).

Statistics

Rotation
not in the set
Weeks in an uptrend
—
Industry in uptrend
16% -15 in 4 wk
Insider buys, 12 months
$318.1M
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
0

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 0 of 0 weeks.

20 Apr – 19 Oct
17%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$306.6MNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months12
Sale orders, 12 months0
Buyers · sellers12 · 0
WhoDidSharesTraded
Orbimed Advisors LlcDirector, 10% ownerbought1,666,667at $18.007 Aug 2026filed 11 Aug 2026
Orbimed Advisors LlcDirector, 10% ownerbought273,333at $18.007 Aug 2026filed 11 Aug 2026
Erez ChimovitsDirector, 10% ownerbought1,666,667at $18.007 Aug 2026filed 11 Aug 2026
Erez ChimovitsDirector, 10% ownerbought273,333at $18.007 Aug 2026filed 11 Aug 2026
Forbion Growth Opportunities Fund Iii Cooperatief U.a.10% ownerbought1,920,000at $18.007 Aug 2026filed 7 Aug 2026
Forbion Growth Opportunities Fund Iii Cooperatief U.a.10% ownerbought1,680,000at $18.007 Aug 2026filed 7 Aug 2026
Ah Bio Fund Iv, L.p.10% ownerbought1,100,000at $18.007 Aug 2026filed 11 Aug 2026
David Charles LubnerDirectorbought55,555at $18.007 Aug 2026filed 7 Aug 2026
Travis MurdochCEO and Presidentbought83,333at $18.007 Aug 2026filed 7 Aug 2026
Michele A. AndersonChief Development Officerbought1,111at $18.007 Aug 2026filed 7 Aug 2026
David I. MalekDirectorbought4,166at $18.007 Aug 2026filed 7 Aug 2026
Christopher ViehbacherDirectorbought83,333at $18.007 Aug 2026filed 7 Aug 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders0
New · exited0 · 0
Reported value$0

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange

Everyone who traded it

AH Bio Fund IV, L.P. Company insider10% owner · last 7 Aug 20261 · 0
Christopher Viehbacher Company insiderDirector · last 7 Aug 20261 · 0
David Charles Lubner Company insiderDirector · last 7 Aug 20261 · 0
David I. Malek Company insiderDirector · last 7 Aug 20261 · 0
Erez Chimovits Company insiderDirector, 10% owner · last 7 Aug 20261 · 0
Forbion Growth Opportunities Fund III Cooperatief U.A. Company insider10% owner · last 7 Aug 20261 · 0
James Paul Rickey Company insiderChief Financial Officer · last 7 Aug 20261 · 0
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Company insider10% owner · last 7 Aug 20260 · 0
Marc L. Andreessen Company insider10% owner · last 7 Aug 20261 · 0
Michele A. Anderson Company insiderChief Development Officer · last 7 Aug 20261 · 0
ORBIMED ADVISORS LLC Company insiderDirector, 10% owner · last 7 Aug 20261 · 0
Orbimed Genesis Gp Llc Company insiderDirector, 10% owner · last 7 Aug 20261 · 0

Same industry

No other stock in its industry this week.

Government contracts

No federal award is tied to it.

From its SEC filings

No ratio computed from its SEC filings yet.

Analyst forecasts

No analyst forecasts yet.